Back to mobile site

Aeglea BioTherapeutics (AGLE) Announces $50M Proposed Public Offering of Common Stock

February 5, 2019 5:16 PM EST Send to a Friend
Aeglea BioTherapeutics, Inc. (Nasdaq: AGLE), a clinical-stage biotechnology company that designs and develops innovative human enzyme therapeutics for patients with ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login